The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review

Judith Bosschieter, Catrin Lutz, Loes I Segerink, André N Vis, Ellen C Zwarthoff, R Jeroen A van Moorselaar, Bas Wg van Rhijn, Martijn W Heymans, Elizabeth P Jansma, Renske Dm Steenbergen, Jakko A Nieuwenhuijzen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

AIM: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.

PATIENTS & METHODS: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.

RESULTS: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.

CONCLUSION: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.

Original languageEnglish
Pages (from-to)673-687
Number of pages15
JournalEpigenomics
Volume10
Issue number5
DOIs
Publication statusPublished - May 2018

Cite this

@article{0ca74a5b775c4df89ff1d47f07b4d981,
title = "The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review",
abstract = "AIM: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.PATIENTS & METHODS: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.RESULTS: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100{\%}) and specificities (0-100{\%}). Considerable heterogeneity across studies was observed and most was case-control studies.CONCLUSION: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.",
author = "Judith Bosschieter and Catrin Lutz and Segerink, {Loes I} and Vis, {Andr{\'e} N} and Zwarthoff, {Ellen C} and {A van Moorselaar}, {R Jeroen} and {van Rhijn}, {Bas Wg} and Heymans, {Martijn W} and Jansma, {Elizabeth P} and Steenbergen, {Renske Dm} and Nieuwenhuijzen, {Jakko A}",
year = "2018",
month = "5",
doi = "10.2217/epi-2017-0156",
language = "English",
volume = "10",
pages = "673--687",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "5",

}

The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer : a systematic review. / Bosschieter, Judith; Lutz, Catrin; Segerink, Loes I; Vis, André N; Zwarthoff, Ellen C; A van Moorselaar, R Jeroen; van Rhijn, Bas Wg; Heymans, Martijn W; Jansma, Elizabeth P; Steenbergen, Renske Dm; Nieuwenhuijzen, Jakko A.

In: Epigenomics, Vol. 10, No. 5, 05.2018, p. 673-687.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer

T2 - a systematic review

AU - Bosschieter, Judith

AU - Lutz, Catrin

AU - Segerink, Loes I

AU - Vis, André N

AU - Zwarthoff, Ellen C

AU - A van Moorselaar, R Jeroen

AU - van Rhijn, Bas Wg

AU - Heymans, Martijn W

AU - Jansma, Elizabeth P

AU - Steenbergen, Renske Dm

AU - Nieuwenhuijzen, Jakko A

PY - 2018/5

Y1 - 2018/5

N2 - AIM: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.PATIENTS & METHODS: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.RESULTS: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.CONCLUSION: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.

AB - AIM: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.PATIENTS & METHODS: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.RESULTS: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.CONCLUSION: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.

U2 - 10.2217/epi-2017-0156

DO - 10.2217/epi-2017-0156

M3 - Article

VL - 10

SP - 673

EP - 687

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 5

ER -